Clin2
NCT06731621Possibly a fitActive, not recruiting

Psilocybin for depression that hasn't responded to treatment in autistic adults

Treatment Resistant DepressionAutism Spectrum Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests whether a single dose of psilocybin can help treat depression in autistic adults who have not gotten better with standard antidepressants. You will be asked to stop your current antidepressant and antipsychotic medications before the study, and you will have several follow-up visits and an MRI scan.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
20 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Be between 18 and 65 years old
  • Have a diagnosis of autism spectrum disorder and current major depressive disorder that has not improved after at least two adequate trials of antidepressants
  • Be willing to stop your current antidepressant and antipsychotic medications for at least 2 weeks before the study starts
  • Not have a history of psychosis, bipolar disorder, or a first-degree relative with these conditions
  • Not use alcohol, cannabis, or other recreational drugs during the study period
  • Have an IQ of 70 or higher, or score above the 10th percentile on a standard reasoning test

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06512220Recruiting· Phase 2
Psilocybin for treatment-resistant depression brain imaging study

This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.

Toronto, Ontario
NCT07211438Recruiting· Phase 2
Psilocybin with Monitors for Treatment-Resistant Depression

This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.

Toronto, Ontario
NCT06378229Recruiting· Phase 2
Psilocybin for hospitalized treatment-resistant depression

This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.

Ghent, Oost-Vlaanderen
NCT07183748Recruiting· Phase 2
Psilocybin microdosing plus therapy for hard-to-treat depression

This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.

Beersheba
NCT07499583Not yet recruiting· Phase 1/Phase 2
Psilocybin therapy for depression and substance use in veterans and first responders

This trial tests whether psilocybin-assisted psychotherapy can help veterans and first responders with treatment-resistant depression and a co-occurring substance use disorder. It aims to see if this approach reduces depression and substance use.

Indianapolis, Indiana
NCT06132178Recruiting· Phase 2
Psilocybin and rTMS for hard-to-treat depression

This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.

Austin, Texas

Hear when a new Treatment Resistant Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.